According to Straits Research, the global Pemetrexed Market size was valued at USD 2.27 billion in 2022 and is projected to grow modestly, reaching USD 2.61 billion by 2031. This growth corresponds to a compound annual growth rate (CAGR) of 1.6% during the forecast period (2023–2031).

Pemetrexed disodium is a chemotherapy drug used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). The generic version of the drug is named pemetrexed. Currently, it is available in powder form, which is then converted to a solution for intravenous infusion. According to Cancer Research U.K., lung cancer is the third most prevalent in the U.K, which accounts for approximately 13% of all the new cancer cases occurring in a year. Moreover, it was the second most common cancer type in males, as 24,500 new cases were registered in 2015. Over the last decade, the prevalence of cancer has increased by 3%, which, in turn, has influenced the pemetrexed market in the U.K.

Get Free Request Sample Report @ https://straitsresearch.com/report/pemetrexed-market/request-sample

Key Market Trends

The Pemetrexed Market is undergoing significant transformations as new therapeutic applications and innovative distribution channels reshape the landscape. Pemetrexed, primarily used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC), remains a critical component of oncology care. The market is characterized by a shift toward targeted therapies and the introduction of biosimilar versions, which aim to enhance accessibility and affordability.

Driving Factors

1. Growing Cancer Incidence: The rising prevalence of cancer worldwide, particularly lung cancers and mesothelioma, has heightened the demand for effective chemotherapeutic agents such as pemetrexed.

2. Advancements in Oncology Treatments: Ongoing research and development in oncology therapies are driving innovations in pemetrexed formulations and combination therapies, enhancing treatment outcomes and expanding its applications.

3. Increased Healthcare Expenditure: Governments and private entities are investing heavily in healthcare infrastructure, particularly in emerging economies, fostering greater adoption of oncology treatments.

Opportunities in the Market

1. Emerging Biosimilars: The expiration of key patents has opened the door for biosimilar versions of pemetrexed, creating opportunities for market expansion and increased competition.

2. Expansion in Emerging Markets: Growing healthcare awareness and improving access to oncology treatments in regions such as Asia-Pacific, Latin America, and the Middle East present untapped potential for market players.

3. Personalized Medicine: Advancements in biomarkers and diagnostic tools are paving the way for personalized medicine, which could further refine the application of pemetrexed in targeted therapies.

Market Segmentation

The Pemetrexed Market is segmented based on application and end-user:

• By Application:

  • Malignant Pleural Mesothelioma

  • Non-Squamous NSCLC

• By End-User:

  • Hospitals

  • Oncology Centers

  • Online Pharmacies

  • Offline Pharmacies

Among these, the hospitals segment remains dominant, given their role as primary treatment hubs for cancer patients. However, online pharmacies are emerging as a significant distribution channel due to their convenience and growing digital healthcare infrastructure.

Key Players in the Pemetrexed Market

Prominent players in the Pemetrexed Market include:

1. Eli Lilly and Company

2. Teva Pharmaceutical Industries Ltd.

3. Pfizer Inc.

4. Mylan N.V.

5. Dr. Reddy’s Laboratories Ltd.

6. Sun Pharmaceutical Industries Ltd.

7. Accord Healthcare Ltd.

8. Sandoz International GmbH

9. Fresenius Kabi

10. Cipla Inc.

These companies are focusing on strategic initiatives such as collaborations, product launches, and expansions into emerging markets to strengthen their positions in the global market.

Buy Now@ https://straitsresearch.com/buy-now/pemetrexed-market

Conclusion

The Pemetrexed Market is poised for steady growth, driven by the increasing prevalence of cancer and advancements in therapeutic options. While challenges such as pricing pressures and regulatory hurdles persist, opportunities in biosimilars and emerging markets are expected to propel the industry forward.

Why Choose Straits Research?

Straits Research is a leading provider of comprehensive market intelligence, delivering actionable insights and in-depth analysis to empower businesses. Our reports are crafted by industry experts to provide a clear understanding of market dynamics, helping stakeholders make informed decisions.

Contact Us

• Email: sales@straitsresearch.com

• Address: 825 3rd Avenue, New York, NY, USA, 10022

• Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)